×

Akers Biosciences Introduces New Rapid Breath Ketone and Oxidative Stress Tests to the Health and Wellness Industry

THOROFARE, N.J., May 12, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, introduced two new breath tests to the U.S. market from the Company's Akers Wellness division at the World Congress on Anti-Aging Medicine in Hollywood, Florida, USA last week.

BreathScan® OxiChekTM ("OxiChek™") and BreathScan® KetoChekTM ("KetoChek™"), together with the Bluetooth®-enabled reading device, BreathScan LyncTM - which synchs via an app on any mobile device - will enable users to monitor trends in critical metabolic processes. The products will provide healthcare professionals, suppliers of nutritional supplements and weight loss plans, as well as health coaches, the ability to more effectively demonstrate, monitor and adjust the efficacy of their products and the progress of their clients. These products may also provide such customers with an opportunity for significant revenue enhancement through distribution for in-office and at-home use of the devices.

OxiChek™ is the first disposable breath test to rapidly determine levels of oxidative stress (free radicals) in the body. OxiChek™ measures the most abundant free radicals, including superoxides, hydrogen peroxide and aldehydes – unlike some pre-existing devices which measure only one. Frequent use of OxiChek™ may help users comply with and adhere to their regimen of nutritional supplementation for management of oxidative stress, which is implicated in many diseases including cardiac, cancer and arthritic diseases.

KetoChek™ is a second generation enhancement of the Company's METRON® breath ketone test. KetoChek™, to our knowledge, is the only disposable breath-based diagnostic device that provides rapid, quantitative assessment of the presence of ketones, to determine if the subject is in the optimal fat-burning state for weight loss, known as ketosis. Achieving a state of ketosis is a goal of many individuals following low carbohydrate, ketogenic diets. KetoChek™ is a simple, non-invasive test to track and monitor for ketosis in individuals interested in maximizing weight loss, as well as endurance athletes wanting to activate fat-burning metabolism.

The innovative BreathScan LyncTM device works with both OxiChek™ and KetoChek™, to display and track results over time via Bluetooth®, to any iOS (Apple) or Android mobile device.

"We believe that personalized health information is the wave of the future and that this suite of BreathScan products, including OxiChek™, KetoChek™ and the BreathScan Lync™, will provide tremendous value to healthcare professionals, consumers, and diet and supplement manufacturers within the health and wellness industry," said Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman.

"Our KetoChek™ test can help individuals achieve ketosis, which is a state of optimal fat burning, while OxiChek™ can help them better optimize lifestyle and supplement utilization to control free radical levels. Since higher free radical levels have been shown to correlate with age, OxiChek™ is providing important information that can greatly enhance an individual's ability to take control of their aging process," continued Dr. Akers.

"Health and wellness is a trillion dollar business globally and our proprietary technology for testing breath condensate is a highly effective diagnostic tool for professionals and consumers in this industry. Whether in health and wellness or medical diagnostics, our faster, easier diagnostic tests provide information that make lives better," added Dr. Akers.

The Company is in discussions with a number of strategic partners specializing in the health and wellness industry with regards to the commercialization of OxiChek™, KetoChek™, and BreathScan Lync™.

ABOUT AKERS BIOSCIENCES, INC.

Akers Biosciences develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical product distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics.

Additional information on the Company and its products can be found at www.akersbiosciences.com. Follow us on Twitter @AkersBio.

Cautionary Statement Regarding Forward Looking Statements

Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the intended terms of the offering, closing of the offering and use of any proceeds from the offering. When used herein, the words "anticipate," "believe," "estimate," "upcoming," "plan," "target", "intend" and "expect" and similar expressions, as they relate to Akers Biosciences, Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.

CONTACT: For more information: Akers Biosciences, Inc. Raymond F. Akers, Jr. PhD Executive Chairman of the Board Tel. +1 856 848 8698 finnCap (UK Nominated Adviser and Broker) Geoff Nash / Scott Mathieson (Corporate Finance) Steve Norcross (Broking) Tel. +44 (0)20 7220 0500 Taglich Brothers, Inc. (US Investor Relations) Chris Schreiber Tel. +1 917 445 6207 Vigo Communications (UK Investor Relations) Ben Simons / Fiona Henson Tel. +44 (0)20 7016 9570 akers@vigocomms.com

Source:Akers Biosciences, Inc.